Filing Flows › Standard Biotools (LAB) › Q2 2026
Standard Biotools (LAB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Standard Biotools (LAB) reported revenue of $20.1M for the second quarter 2026 (Q2 2026), -8% from a year earlier and -5% from the quarter before. Operating margin was -126.3%, net loss $26.8M (133.1% of revenue).
Standard Biotools, Q2 2026: revenue $20.1M (-8% year over year), operating margin -126.3%, net loss $26.8M, operating cash flow −$10.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.1M | -5% | -8% |
| Operating profit | −$25.4M | — | — |
| Net earnings | −$26.8M | -121% | — |
| Operating cash flow | −$10.3M | — | — |
What changed
Revenue was $20.1M in Q2 2026, down 8% year over year and down 5% from the previous quarter. Consumables was the largest line at 47% of revenue. Consumables lost $1.1M year over year (down 10%), 65% of the total change.
Gross margin was 52.4%, up 3.6 points from Q2 2025. Operating costs exceeded revenue by $25.4M, an operating margin of -126.3%. Operating expenses fell 1% while revenue fell 8%. The fastest-growing cost line was Other operating costs (+779%). The quarter ended with a net loss of $26.8M, after a profit of $127.1M the previous quarter.
Operating cash flow was −$10.3M. Non-cash charges added back $1.3M of depreciation and amortization and $4.0M of share-based compensation. Working capital and other items added $11.1M. Capital expenditures of $344K exceeded it, leaving free cash flow of −$10.7M.
Questions
What was Standard Biotools' revenue in the second quarter 2026?
Standard Biotools (LAB) reported revenue of $20.1M for the second quarter 2026 (Q2 2026), -8% from a year earlier and -5% from the quarter before.
Was Standard Biotools profitable in the second quarter 2026?
Operating loss was $25.4M (-126.3% of revenue) and net loss $26.8M.
Source: Standard Biotools 10-Q on SEC EDGAR.